ScienceDaily PharmaceuticalsOriginal article
Stopping Ozempic may raise heart attack and stroke risk
Data ReadoutnegativeOzempicWegovyMounjaroNegative
AI Analysis
Summary
A large study reports that cardiovascular benefits of GLP-1 drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound rapidly diminish upon treatment discontinuation, with patients showing 22% higher risk of major adverse cardiovascular events after two years off medication compared to those continuing treatment.
Outcome Details
Study shows cardiovascular benefits of GLP-1 drugs disappear after treatment cessation, with 22% higher risk of heart attack, stroke, and death after two years off medication compared to continued treatment
Importance:6/10
Sentiment:
-0.70
GLP-1 agonistscardiovascular riskdrug discontinuationobservational studyheart attackstroke
Read the original article
Published by ScienceDaily Pharmaceuticals on September 21, 2026 1:35 PM